- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – 

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both chemotherapy-related -

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today shared comments following the recent FDA approval of a new second-line pancreatic cancer treatment.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.